SVB Leerink analyst Puneet Souda views Guardant Health as a best-in-class liquid biopsy opportunity in a massive high growth market, with the company generating a conservative 60% revenue CAGR that is likely to accelerate as the overall LBx market grows. The analyst highlights buying opportunity amid recent weakness, and reiterates an Outperform rating and $130 price target on the shares given the catalyst path ahead over the next year.

Craig-Hallum assumed coverage of Guardant Health with a Buy rating with a price target of $28, down from $54. The firm remains bullish about the opportunities in therapy selection and are not all that concerned about emerging competition in liquid biopsy. Further, it is also bullish about the potential for Reveal, over time. Craig-Hallum thinks that there is a significant market for a tumor-naive MRD test. Tissue is simply not an option for all patients. Guardant appears to have the most viable test. Additionally, the firm believes the Shield colorectal screening test will be commercially viable, if FDA approved. The consensus view seems to be that there is no chance for this test to be included in the next USPSTF colon cancer screening recommendation. Craig-Hallum thinks that there is a reasonable likelihood that it will be included.